Baricitinib: From Rheumatoid Arthritis to COVID-19

April 2021 in “ Journal of clinical pharmacology ”

Sara Assadiasl, Yousef Fatahi, Banafsheh Mosharmovahed, Bahareh Mohebbi, Mohammad Hossein Nicknam

baricitinib JAK1/2 inhibitor alopecia areata hair regrowth

From the encyclopedia

JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Studysummary This review discusses baricitinib's applications for various inflammatory disorders and highlights its promising efficacy alongside potential adverse effects, advocating for further research before it becomes a standard treatment.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

Baricitinib, a JAK1/2 inhibitor initially approved for rheumatoid arthritis, has shown efficacy in treating various inflammatory and autoimmune diseases, including COVID-19, systemic lupus erythematosus, psoriasis, atopic dermatitis, and alopecia areata. Clinical trials have demonstrated significant improvements in disease activity and symptoms across these conditions, with notable hair regrowth in alopecia areata patients. However, its use is associated with adverse effects such as infections, liver enzyme dysregulation, and potential malignancies, necessitating careful monitoring and further research to fully understand its safety profile and optimize treatment regimens.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

2 / 2 results

research Treatment of Severe Alopecia Areata with Baricitinib

25 citations , October 2019 in “JAAD Case Reports”

This article discusses the role of interleukin-15 and Janus kinase inhibitors in alopecia areata based on a murine model and reports no new experimental results.

research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

184 citations , February 2015 in “EBioMedicine”

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.